NCT07004322View on ClinicalTrials.gov

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

April 7, 2026

Study Completion Date

April 7, 2026

Conditions
Diabetes Mellitus, Type 2Obesity
Interventions
DRUG

NNC0519-0130

NNC0519-0130 will be administered subcutaneously.

DRUG

Placebo

Placebo matched to NNC0519-0130 will be administered subcutaneously.

Trial Locations (1)

100089

RECRUITING

Peking University Third Hospital, Northern branch-Phase I, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT07004322 - A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight | Biotech Hunter | Biotech Hunter